September 2019
Issue
Supplement
Guest Chief Medical Editors’ Page
After the Meta-Analysis…
By Sabine Steiner, MD; and Ramon L. Varcoe, MBBS, MS, FRACS, PhD
COVER STORIES
Nine Months Later… An Interview With Konstantinos Katsanos, MD
Dr. Katsanos’s thoughts regarding the vascular community’s reaction to his group’s meta-analysis, the potential influence of follow-up and adjudication variables, non-SFA applications, and what comes next.
With Konstantinos Katsanos, MSc, MD, PhD, EBIR
Panel Discussion: Exploring the Paclitaxel Safety Signal
Experts discuss considerations in trial design, adjudication, and paths forward.
With Marianne Brodmann, MD; William Gray, MD; Peter A. Schneider, MD; Ramon L. Varcoe, MBBS, MS, FRACS, PhD; and Thomas Zeller, MD, PhD
Paclitaxel Post-Panel: FDA Discusses What’s Next From a Regulatory Perspective
An interview with representatives from the FDA Center for Devices and Radiological Health on the key updates to the letter to health care providers, lessons learned for future trials and follow-up protocols, and additional plans for monitoring in the future.
With Eleni Whatley, PhD; and Andrew Farb, MD
Ask the Experts: How Do You Define ‘High Risk for Restenosis’?
With Gary M. Ansel, MD; Herbert D. Aronow, MD, MPH, FACC, FSCAI, FSVM; Marianne Brodmann, MD; Koen Deloose, MD; Andrew Holden, MBChB, FRANZCR, EBIR; John H. Rundback, MD; and Peter A. Schneider, MD
Understanding the Paclitaxel Dose Effect
Answers to key questions about the paclitaxel controversy, including why the dose-response effect discussion is important and the impact of improved patient-level data collection.
By Andrew Holden, MBChB, FRANZCR, EBIR
Real-World Data Collection Regarding Paclitaxel Treatment
An overview of why real-world data are pertinent to the safety assessment of paclitaxel-coated devices, with separate summaries of the projects investigating the late mortality signal via real-world data analyses.
By Anna Krawisz, MD; and Eric A. Secemsky, MD
Medicare Database Project
By Anna Krawisz, MD, and Eric A. Secemsky, MD
Optum Database Project
By Robert Yeh, MD, and Eric A. Secemsky, MD
Society for Vascular Surgery Vascular Quality Initiative
By Daniel Bertges, MD
American College of Cardiology National Cardiovascular Data Registry
By William Schuyler Jones, MD
The Natural History of Intermittent Claudication
Considering atypical presentations of symptomatic peripheral artery disease and the associated major adverse events.
By Amit N. Keswani, MD; and Joshua A. Beckman, MD
A Retrospective Look at Paclitaxel Use in the Coronary Arteries
A review of the safety and efficacy profile of paclitaxel treatment in patients with coronary artery disease.
By Mark K. Tuttle, MD; and Jeffrey J. Popma, MD
Lesion-Specific SFA Device Selection
Key questions to consider for accurate diagnoses and tailored treatment decisions.
By Koen Deloose, MD
Pipeline Report: A Look at Next-Generation SFA Technologies
A review of the recent advances in lesion crossing, atherectomy, vessel preparation, and drug delivery technologies.
By Sabine Steiner, MD; and Andrej Schmidt, MD
FEATURED TECHNOLOGY
Sponsored by Ra Medical Systems, Inc.Case Report: Severe Common Femoral Artery Disease and Failed Femoropopliteal Artery Graft: Amputation Avoided Through Use of DABRA Excimer Laser in an OBL Setting
By Mubashar Choudry, MD, FACC; Rashid A. Chotani, MD, MPH, FRCPH; James Rothstein, MD; and Amit Kumar Rajvanshi, MD
Swirling Flow®: Nature’s Ideal Alternative to Drug Elution
How swirling flow induced by the BioMimics 3D stent provides a drug-free solution for limiting restenosis and reducing the need for revascularization.
By Peter Gaines, MD, MRCP, FRCR
EUROPEAN FEATURED TECHNOLOGY
Sponsored by Penumbra, Inc.Indigo System for Peripheral Arterial Clot Management
With Gianmarco de Donato, MD; Theodosios Bisdas, MD; Costantino Del Giudice, MD, PhD; Katharine Lewis, MBBS, FRCR, FHEA; Mario Corona, MD; Pierleone Lucatelli, MD; and Martin Schröder, MD
MEDICAL AFFAIRS CORNER
Sponsored by MedtronicIN.PACT™ Admiral™ DCB: Safety and Effectiveness in Treating Complex Lesions
Weighing the risks and benefits when treating complex lesions in the femoropopliteal vascular bed.
By Gary M. Ansel, MD, FACC
DEPARTMENTS
European Innovations
An Interview With Patrick Chong, MBBS, FRCS (Eng), FRCS (Gen Surg)
Mr. Chong discusses the current status of the BASIL-3 trial, NICE AAA guidance, and his advice for engaging in online clinical discussion platforms.
advertisement
Top 5 Articles From September 2019
Nine Months Later… An Interview With Konstantinos Katsanos, MD
Dr. Katsanos’s thoughts regarding the vascular community’s reaction to his group’s meta-analysis, the potential influence of follow-up and adjudication variables, non-SFA applications, and what comes next.
With Konstantinos Katsanos, MSc, MD, PhD, EBIR
After the Meta-Analysis…
By Sabine Steiner, MD; and Ramon L. Varcoe, MBBS, MS, FRACS, PhD
Ask the Experts: How Do You Define ‘High Risk for Restenosis’?
With Gary M. Ansel, MD; Herbert D. Aronow, MD, MPH, FACC, FSCAI, FSVM; Marianne Brodmann, MD; Koen Deloose, MD; Andrew Holden, MBChB, FRANZCR, EBIR; John H. Rundback, MD; and Peter A. Schneider, MD
Lesion-Specific SFA Device Selection
Key questions to consider for accurate diagnoses and tailored treatment decisions.
By Koen Deloose, MD
Panel Discussion: Exploring the Paclitaxel Safety Signal
Experts discuss considerations in trial design, adjudication, and paths forward.
With Marianne Brodmann, MD; William Gray, MD; Peter A. Schneider, MD; Ramon L. Varcoe, MBBS, MS, FRACS, PhD; and Thomas Zeller, MD, PhD
Top 5 from CIToday's Current Issue
Massive Thromboembolism, PFO, and Acute Limb Ischemia
By Moderator: Mohamad Alkhouli, MD
Panelists: Yashu Dhamija, MD; Abdul Moiz Hafiz, MD; Ankur Kalra, MD, FACP, FACC, FSCAI; and Anmar Kanaa’N, MD
Meeting the Challenge…
By Azeem Latib, MD
Compensation and Production Trends for Interventionalists
A look at MedAxiom’s annual report reflecting the continued evolution of the field in terms of physician demand and compensation agreements.
